By Professor Andrew David Carr

Journal articles

Carr AD; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell J; Cahn PE; Chaves R, 2008, 'Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults', AIDS, 22, pp. 2313 - 2321

Monforte A; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law MG; de Witt S; Friis-Moller N; Phillips AN; Sabin C; Lundgren JD, 2008, 'HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.', AIDS, pp. 2143 - 2153

Lundgren JD; Babiker AG; El-Sadr W; Emery S; Grund B; Neaton JD; Neuhaus J; Phillips A, 2008, 'Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4(+) cell counts and HIV RNA levels during follow-up', Journal of Infectious Diseases, 197, pp. 1145 - 1155, http://dx.doi.org/10.1086/529523

Phillips AN; Carr AD; Neuhaus J; Visnegarwala F; Prineas R; Burman W; Williams IR; Drummond F; Duprez D; Belloso WH; Goebel F; Grund B; Hatzakis A; Vera J; Lundgren JD, 2008, 'Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial', Antiviral Therapy, 13, pp. 177 - 187

Emery S; Neuhaus J; Phillips A; Babiker AG; Cohen C; Gatell J; Girard P; Grund B; Law MG; Losso MH; Palfreeman A; Wood R, 2008, 'Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study', Journal of Infectious Diseases, 197, pp. 1133 - 1144, http://dx.doi.org/10.1086/586713

Carr AD, 2008, 'Pathogenesis of cardiovascular disease in HIV infection', Current opinion in HIV & AIDS, 3, pp. 234 - 239

El-Sadr W; Grund B; Neuhaus J; Babiker AG; Cohen C; Darbyshire JH; Emery S; Phillips A; Lundgren JD; Neaton JD, 2008, 'Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial', Annals of Internal Medicine, 149, pp. 289 - W62

Arenas-Pinto A; Copas A; Weller I; Grant A; Dunn D; Bhaskaran K; Carr A; Reiss P; Edwards S; Worm SW; Overton T; Martinez E; Hoy J; Cahn P; Weber R, 2007, 'Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy', AIDS, 21, pp. 2455 - 2464, http://dx.doi.org/10.1097/QAD.0b013e3282f08cdc

Carr A, 2007, 'Treatment strategies for HIV lipodystrophy', Current Opinion in HIV and AIDS, 2, pp. 332 - 338, http://dx.doi.org/10.1097/COH.0b013e3281df2b57

Ellis KJ; Grund B; Visnegarwala F; Thackeray L; Miller CG; Chesson CE; El-Sadr W; Carr A, 2007, 'Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site', Obesity, 15, pp. 1441 - 1447, http://dx.doi.org/10.1038/oby.2007.172

Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K; Staszewski S; Weiss L; Lundgren DJ; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ferrari I; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lanusse I; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; Sanchez MDL; Somenzini C; Tocci M; Algar S; Anderson J; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Britton P; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Egan C; Ferguson W; Finlayson R; French M; Frater A; Gold J; Habel P; Haig K; Holland R; Hyland N; Hoy J; Hudson J; James R; Leung J; Lowe K; MacRae K; McMurchie M; Medland N; Miller S; Murray J; Newman R; David O; Patching J; Primrose R; Ree H; Richardson R; Rogers G; Roney J; Roth N; Sarangapany J; Shaw D; Silberberg C; Skett A; Vale R; Villella C; Walker A; Watson A; Wendt N; Wood H, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x

Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A, 2007, 'Erratum: Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia (Diabetes Care (2007) 30, (113-119))', Diabetes Care, 30, pp. 455, http://dx.doi.org/10.2337/dc07-er02

May M; Sterne JA; Shipley M; Brunner E; d Agostino R; Whincup P; Ben-Shlomo Y; Carr AD; Ledergerber B; Lundgren JD; Phillips A; Massaro J; Eggerl M, 2007, 'A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men', International Journal of Epidemiology, 36, pp. 1309 - 1318

Boyd MA; Truman M; Hales GP; Anderson JS; Dwyer DE; Carr AD, 2007, 'A randomized study to evaluate injection site reactions (ISR) using three different mechanisms for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge needle and a needle-free device', Antiviral Therapy, 12, pp. L57 - L57

Carey DL; Baker D; Rogers G; Petoumenos K; Chuah J; Easey N; Mahon K; Cooper DA; Emery S; Carr AD, 2007, 'A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46, pp. 581 - 589

Calmy A; Hirschel B; Cooper DA; Carr AD, 2007, 'Clinical update: adverse effects of antiretroviral therapy', Lancet, 370, pp. 12 - 14

Calmy A; Petoumenos K; Lewden C; Law MG; Bocquentin F; Hesse K; Cooper DA; Carr AD; Bonnet F, 2007, 'Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts', HIV Medicine, 8, pp. 171 - 180

Prineas R; Roediger M; Carr AD; El-Sadr W; Esser S; Grandits G; Knysz B; Palfreeman A, 2007, 'Effect of alternate treatment protocols on the incidence of electrocardiographic abnormalities among HIV-infected adults in the SMART trial', Antiviral Therapy, 12, pp. L11 - L11

Carr AD; Zajdenverg R; Workman C; Gatell J; Cahn PE; Ritzhaupt A; Zhang W; Chaves R, 2007, 'Effects of tipranavir/r (500/200 or 500/100 mg BID) in comparison with lopinavir/r (400/100 ing BID) on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks', Antiviral Therapy, 12, pp. L8 - L9

Wand HC; Calmy A; Carey DL; Samaras K; Carr AD; Law MG; Cooper DA; Emery S, 2007, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', AIDS, 21, pp. 2445 - 2453

Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2007, 'Prevalence of Metabolic Syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria', Diabetes Care, 30, pp. 113 - 119, http://dx.doi.org/10.2337/dc06-1075

Carr A; Ory D, 2006, 'Does HIV cause cardiovascular disease?', PLoS Medicine, 3, pp. 1986 - 1987, http://dx.doi.org/10.1371/journal.pmed.0030496

Collins S; Mertenskoetter T; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; Weber R; Reisswafaamel-Sadr P; Kirk O; Dabis F; Law MG; Pradier C; De Wit S; Akerlund B; Calvo G; Monforte ADA; Ledergerber B; Phillips AN; De Wolf F; Zaheri S; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JKME; Geerlings SE; Godfried MH; Lange JMA; Van Leth FC; Lowe SH; Van Der Meer JTM; Nellen FJB; Pogány K; Van Der Poll T; Reiss P; Ruys TA; Sankatsing SU; Steingrover R; Van Twillert G; Van Der Valk M; Van Vonderen MGA; Vrouenraets SME; Van Vugt MV; Wit FWMN; Van Eeden A; Ten Veen JH; Van Dam PS; Roos JC; Brinkman K; Frissen PHJ; Weigel HM; Mulder JW; Van Gorp ECM; Meenhorst PL; Mairuhu ATA; Veenstra J; Danner SA; Van Agtmael MA; Claessen FAP; Perenboom RM; Rijkeboer A; Richter C; Van Der Berg J; Van Leusen R; Vriesendorp R; Jeurissen FJF; Kauffmann RH; Koger ELW; Bravenboer B; Ten Napel CHH; Kootstra GJ; Sprenger HG; Miesen WMAJ; Doedens R; Scholvinck EH; Ten Kate RW; Van Houte DPF; Polee M; Kroon FP; Van Den Broek PJ; Van Dissel JT; Schippers EF; Schreij G; Van De Geest S, 2006, 'Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study', Archives of Internal Medicine, 166, pp. 1632 - 1641, http://dx.doi.org/10.1001/archinte.166.15.1632

Boyd MA; Carr AD; Ruxrungtham K; Srasuebkul P; Bien D; Law MG; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange J; Phanuphak P; Cooper DA; Reiss P, 2006, 'Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to Ritonavir-boosted Indinavir and Efavirenz', Journal of Infectious Diseases, 194, pp. 642 - 650

Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2006, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition and metabolic parameters', Antiviral Therapy, 11, pp. L23 - L24

Calmy A; Carey DL; Mallon PW; Wand HC; Cooper DA; Law MG; Carr AD, 2006, 'Early changes in adiponectin and leptin levels predict changes in limb fat mass over 2 years following initiation of antiretroviral therapy', Antiviral Therapy, 11, pp. L12 - L12

Mallon PW; Miller JE; Kovacic JC; Kent-Hughes J; Norris RP; Samaras K; Feneley MP; Cooper DA; Carr AD, 2006, 'Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study', AIDS, 20, pp. 1003 - 1010

Pett SL; Wand HC; Law MG; Arduino R; Lopez JC; Knysz B; Pereira L; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85

Law MG; Puls R; Cheng A; Cooper DA; Carr AD, 2006, 'Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults', Antiviral Therapy, 11, pp. 179 - 186

Carr AD, 2006, 'Investigating new antiretroviral combinations', Journal of Infectious Diseases, 193, pp. 1742 - 1742

Hamlyn E; McAllister J; Winston A; Sinclair B; Amin J; Carr AD; Cooper DA, 2006, 'Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?', Sexually Transmitted Infections, 82, pp. 21 - 23

Winston A; Amin J; Marriott D; Mallon PW; Carr AD; Cooper DA; Emery S, 2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, 7, pp. 105 - 111

Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders J; Petoumenos K; Irvine K; Law MG; Grey PA; Finlayson R; Mcfarlane R; Kelleher AD; Carr AD; Cooper DA, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202

Shulman N; Moyle G; Carr A; Boyle B, 2005, '12th Conference on Retroviruses and Opportunistic Infections (CROI). February 22-25, 2005; Boston, Massachusetts, USA', HIV Clinical Trials, 6, pp. 169 - 181, http://dx.doi.org/10.1310/EYBU-95QU-J9JM-JC1E

Behrens GMN; Grinspoon S; Carr A, 2005, 'Cardiovascular risk and body-fat abnormalities in HIV-infected adults [4] (multiple letters)', New England Journal of Medicine, 352, pp. 1721 - 1722, http://dx.doi.org/10.1056/NEJM200504213521620

Grinspoon S; Carr A, 2005, 'Cardiovascular risk and body-fat abnormalities in HIV-infected adults', New England Journal of Medicine, 352, pp. 48 - 62, http://dx.doi.org/10.1056/NEJMra041811

Petoumenos K; Ringland C, 2005, 'Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database', HIV Medicine, 6, pp. 155 - 163

Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387

Mallon PW; Wand HC; Law MG; Miller J; Cooper DA; Carr AD, 2005, 'Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38, pp. 156 - 162, http://journals.lww.com/jaids/Fulltext/2005/02010/Buffalo_Hump_Seen_in_HIV_Associated_Lipodystrophy.6.aspx

Grinspoon SK; Carr AD, 2005, 'Cardiovascular risk and body-fat abnormalities in HIV-infected adults - Reply', New England Journal of Medicine, 352, pp. 1722 - 1722

Mallon PW; Miller JM; Kovacic JC; Kent-Hughes J; Norris RP; Samaras K; Feneley MP; Cooper DA; Carr AD, 2005, 'Changes in body composition and cardiovascular measures in hypercholesterolaemic HIV-infected men treated with pravastatin: a randomized, placebo-controlled study', Antiviral Therapy, 10, pp. L15 - L16

El-Sadr W; Mullin C; Carr AD; Gibert C; Rappoport C; Visnegarwala F; Grunfeld C; Raghavan S, 2005, 'Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort', HIV Medicine, 6, pp. 114 - 121

Carey DL; Wand HC; Martin A; Rothwell S; Emery S; Cooper DA; Carr AD, 2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, 19, pp. 1325 - 1327

Sedwell R; Mallon PW; Duarte NL; Zaunders J; Kelleher AD; Cooper DA; Carr AD, 2005, 'Impaired mitochondrial function induced by NRTIs is only detectable in the monocyte (CD14(+)) subset of human PBMC', Antiviral Therapy, 10, pp. L44 - L45

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, 191, pp. 1686 - 1696

Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2005, 'Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors', Antiviral Therapy, 10, pp. L5 - L5

Kovacic JC; Martin A; Carey DL; Wand HC; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr AD, 2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143

Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Ganning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray JM; Gerlach W; Sun L; Penny R; Symonds GP; Carr AD; Cooper DA, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients', Journal of Gene Medicine, 7, pp. 552 - 564

Grinspoon SK; Carr AD, 2005, 'Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults', New England Journal of Medicine, 352, pp. 48 - 62

Mallon PW; Sedwell R; Unemori P; Kelleher AD; Cooper DA; Carr AD, 2005, 'Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy', Antiviral Therapy, 10, pp. M101 - M108

Back to profile page